Arrowhead Pharmaceuticals Inc Key Opinion Leader Webinar on ARO-ENaC Transcript
(technical difficulty)
All in the event. I would now like to turn the call over to your host, Vince Anzalone, Vice President of Investor Relations at Arrowhead Pharmaceuticals. Please go ahead, sir.
(technical difficulty)
Okay. Thanks so much, and sorry for the delay. Sara, if you can switch to the next slide. Okay, and thanks, everybody. Before we start, I just want to remind you that we will be making forward-looking statements on today's presentation. So please refer to risk factors in our regulatory filings.
Next slide, please. Next slide. So we are very lucky today to have a great panel to talk about ENaC, our first pulmonary TRIM-enabled candidate targeting cystic fibrosis. And the key opinion leader that we have joining us today is Dr. Marcus Mall, who is the Professor and Director of the Department of Pediatric Pulmonology and Immunology at the Charité University Medical Center in Berlin. He is a world expert in CF and on alternative target to CF like, such as
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
